The Use of Candida Pyralidae and Pichia Kluyveri to Control Spoilage Microorganisms of Raw Fruits Used for Beverage Production
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
The Role and Use of Non-Saccharomyces Yeasts in Wine Production
The Role and Use of Non-Saccharomyces Yeasts in Wine Production N.P. Jolly1*, O.P.H. Augustyn1 and I.S. Pretorius2** (1) ARC Infruitec-Nietvoorbij***, Private Bag X5026, 7599 Stellenbosch, South Africa. (2) Institute for Wine Biotechnology, Department of Viticulture & Oenology, Stellenbosch University, Private Bag X1, 7602 Matieland (Stellenbosch), South Africa. Submitted for publication: September 2005 Accepted for publication: April 2006 Key words: Non-Saccharomyces, yeasts, vineyards, cellars, fermentation, wine. The contribution by the numerous grape-must-associated non-Saccharomyces yeasts to wine fermentation has been debated extensively. These yeasts, naturally present in all wine fermentations, are metabolically active and their metabolites can impact on wine quality. Although often seen as a source of microbial spoilage, there is substantial contrary evidence pointing to a positive contribution by these yeasts. The role of non-Saccharomyces yeasts in wine fermentation is therefore receiving increasing attention by wine microbiologists in Old and New World wine producing countries. Species that have been investigated for wine production thus far include those from the Candida, Kloeckera, Hanseniaspora, Zygosaccharomyces, Schizosaccharomyces, Torulaspora, Brettanomyces, Saccharomycodes, Pichia and Williopsis genera. In this review the use and role of non-Saccharomyces yeast in wine production is presented and research trends are discussed. INTRODUCTION roles of the numerous non-Saccharomyces yeasts normally asso- ciated with grape must and wine. These yeasts, naturally present Wine is the product of a complex biological and biochemical in all wine fermentations to a greater or lesser extent, are meta- interaction between grapes (grape juice) and different microor- bolically active and their metabolites can impact on wine quality. -
Austin Ultrahealth Yeast-Free Protocol 1
1 01/16/12/ Austin UltraHealth Yeast-Free Protocol 1. Follow the Yeast Diet in your binder for 6 weeks or you may also use recipes from the Elimination Diet. (Just decrease the amount of grains and fruits allowed). 2. You will be taking one pill of prescription antifungal daily, for 30 days. This should always be taken two hours away from your probiotics. This medication can be very hard on your liver so it is important to refrain from ALL alcohol while taking this medication. Candida Die-Off Some patients experience die-off symptoms while eliminating the yeast, or Candida, in their gut. Die off symptoms can include the following: Brain fog Dizziness Headache Floaters in the eyes Anxiety/Irritability Gas, bloating and/or flatulence Diarrhea or constipation Joint/muscle pain General malaise or exhaustion What Causes Die-Off Symptoms? The Candida “die-off” occurs when excess yeast in the body literally dies off. When this occurs, the dying yeasts produce toxins at a rate too fast for your body to process and eliminate. While these toxins are not lethal to the system, they can cause an increase in the symptoms you might already have been experiencing. As the body works to detoxify, those Candida die-off symptoms can emerge and last for a matter of days, or weeks. The two main factors which cause the unpleasant symptoms of Candida die off are dietary changes and antifungal treatments, both of which you will be doing. Dietary Changes: When you begin to make healthy changes in your diet, you begin to starve the excess yeasts that have been hanging around, using up the extra sugars in your blood. -
Candida Auris
microorganisms Review Candida auris: Epidemiology, Diagnosis, Pathogenesis, Antifungal Susceptibility, and Infection Control Measures to Combat the Spread of Infections in Healthcare Facilities Suhail Ahmad * and Wadha Alfouzan Department of Microbiology, Faculty of Medicine, Kuwait University, P.O. Box 24923, Safat 13110, Kuwait; [email protected] * Correspondence: [email protected]; Tel.: +965-2463-6503 Abstract: Candida auris, a recently recognized, often multidrug-resistant yeast, has become a sig- nificant fungal pathogen due to its ability to cause invasive infections and outbreaks in healthcare facilities which have been difficult to control and treat. The extraordinary abilities of C. auris to easily contaminate the environment around colonized patients and persist for long periods have recently re- sulted in major outbreaks in many countries. C. auris resists elimination by robust cleaning and other decontamination procedures, likely due to the formation of ‘dry’ biofilms. Susceptible hospitalized patients, particularly those with multiple comorbidities in intensive care settings, acquire C. auris rather easily from close contact with C. auris-infected patients, their environment, or the equipment used on colonized patients, often with fatal consequences. This review highlights the lessons learned from recent studies on the epidemiology, diagnosis, pathogenesis, susceptibility, and molecular basis of resistance to antifungal drugs and infection control measures to combat the spread of C. auris Citation: Ahmad, S.; Alfouzan, W. Candida auris: Epidemiology, infections in healthcare facilities. Particular emphasis is given to interventions aiming to prevent new Diagnosis, Pathogenesis, Antifungal infections in healthcare facilities, including the screening of susceptible patients for colonization; the Susceptibility, and Infection Control cleaning and decontamination of the environment, equipment, and colonized patients; and successful Measures to Combat the Spread of approaches to identify and treat infected patients, particularly during outbreaks. -
Candida Species Identification by NAA
Candida Species Identification by NAA Background Vulvovaginal candidiasis (VVC) occurs as a result of displacement of the normal vaginal flora by species of the fungal genus Candida, predominantly Candida albicans. The usual presentation is irritation, itching, burning with urination, and thick, whitish discharge.1 VVC accounts for about 17% to 39% of vaginitis1, and most women will be diagnosed with VVC at least once during their childbearing years.2 In simplistic terms, VVC can be classified into uncomplicated or complicated presentations. Uncomplicated VVC is characterized by infrequent symptomatic episodes, mild to moderate symptoms, or C albicans infection occurring in nonpregnant and immunocompetent women.1 Complicated VVC, in contrast, is typified by severe symptoms, frequent recurrence, infection with Candida species other than C albicans, and/or occurrence during pregnancy or in women with immunosuppression or other medical conditions.1 Diagnosis and Treatment of VVC Traditional diagnosis of VVC is accomplished by either: (i) direct microscopic visualization of yeast-like cells with or without pseudohyphae; or (ii) isolation of Candida species by culture from a vaginal sample.1 Direct microscopy sensitivity is about 50%1 and does not provide a species identification, while cultures can have long turnaround times. Today, nucleic acid amplification-based (NAA) tests (eg, PCR) for Candida species can provide high-quality diagnostic information with quicker turnaround times and can also enable investigation of common potential etiologies -
Candida & Nutrition
Candida & Nutrition Presented by: Pennina Yasharpour, RDN, LDN Registered Dietitian Dickinson College Kline Annex Email: [email protected] What is Candida? • Candida is a type of yeast • Most common cause of fungal infections worldwide Candida albicans • Most common species of candida • C. albicans is part of the normal flora of the mucous membranes of the respiratory, gastrointestinal and female genital tracts. • Causes infections Candidiasis • Overgrowth of candida can cause superficial infections • Commonly known as a “yeast infection” • Mouth, skin, stomach, urinary tract, and vagina • Oropharyngeal candidiasis (thrush) • Oral infections, called oral thrush, are more common in infants, older adults, and people with weakened immune systems • Vulvovaginal candidiasis (vaginal yeast infection) • About 75% of women will get a vaginal yeast infection during their lifetime Causes of Candidiasis • Humans naturally have small amounts of Candida that live in the mouth, stomach, and vagina and don't cause any infections. • Candidiasis occurs when there's an overgrowth of the fungus RISK FACTORS WEAKENED ASSOCIATED IMUMUNE SYSTEM FACTORS • HIV/AIDS (Immunosuppression) • Infants • Diabetes • Elderly • Corticosteroid use • Antibiotic use • Contraceptives • Increased estrogen levels Type 2 Diabetes – Glucose in vaginal secretions promote Yeast growth. (overgrowth) Treatment • Antifungal medications • Oral rinses and tablets, vaginal tablets and suppositories, and creams. • For vaginal yeast infections, medications that are available over the counter include creams and suppositories, such as miconazole (Monistat), ticonazole (Vagistat), and clotrimazole (Gyne-Lotrimin). • Your doctor may prescribe a pill, fluconazole (Diflucan). The Candida Diet • Avoid carbohydrates: Supporters believe that Candida thrives on simple sugars and recommend removing them, along with low-fiber carbohydrates (eg, white bread). -
GRAS Notice for Pichia Kudriavzevii ASCUSDY21 for Use As a Direct Fed Microbial in Dairy Cattle
GRAS Notice for Pichia kudriavzevii ASCUSDY21 for Use as a Direct Fed Microbial in Dairy Cattle Prepared for: Division of Animal Feeds, (HFV-220) Center for Veterinary Medicine 7519 Standish Place Rockville, Maryland 20855 Submitted by: ASCUS Biosciences, Inc. 6450 Lusk Blvd Suite 209 San Diego, California 92121 GRAS Notice for Pichia kudriavzevii ASCUSDY21 for Use as a Direct Fed Microbial in Dairy Cattle TABLE OF CONTENTS PART 1 – SIGNED STATEMENTS AND CERTIFICATION ................................................................................... 9 1.1 Name and Address of Organization .............................................................................................. 9 1.2 Name of the Notified Substance ................................................................................................... 9 1.3 Intended Conditions of Use .......................................................................................................... 9 1.4 Statutory Basis for the Conclusion of GRAS Status ....................................................................... 9 1.5 Premarket Exception Status .......................................................................................................... 9 1.6 Availability of Information .......................................................................................................... 10 1.7 Freedom of Information Act, 5 U.S.C. 552 .................................................................................. 10 1.8 Certification ................................................................................................................................ -
Challenges of the Non-Conventional Yeast Wickerhamomyces Anomalus in Winemaking
fermentation Review Challenges of the Non-Conventional Yeast Wickerhamomyces anomalus in Winemaking Beatriz Padilla 1, Jose V. Gil 2,3 and Paloma Manzanares 2,* 1 INCLIVA Health Research Institute, 46010 Valencia, Spain; [email protected] 2 Department of Biotechnology, Instituto de Agroquímica y Tecnología de Alimentos (IATA), Consejo Superior de Investigaciones Científicas (CSIC), Paterna, 46980 Valencia, Spain; [email protected] 3 Departamento de Medicina Preventiva y Salud Pública, Ciencias de la Alimentación, Toxicología y Medicina Legal, Facultad de Farmacia, Universitat de València, Burjassot, 46100 Valencia, Spain * Correspondence: [email protected]; Tel.: +34-96 390-0022 Received: 27 July 2018; Accepted: 18 August 2018; Published: 20 August 2018 Abstract: Nowadays it is widely accepted that non-Saccharomyces yeasts, which prevail during the early stages of alcoholic fermentation, contribute significantly to the character and quality of the final wine. Among these yeasts, Wickerhamomyces anomalus (formerly Pichia anomala, Hansenula anomala, Candida pelliculosa) has gained considerable importance for the wine industry since it exhibits interesting and potentially exploitable physiological and metabolic characteristics, although its growth along fermentation can still be seen as an uncontrollable risk. This species is widespread in nature and has been isolated from different environments including grapes and wines. Its use together with Saccharomyces cerevisiae in mixed culture fermentations has been proposed to increase wine particular characteristics. Here, we review the ability of W. anomalus to produce enzymes and metabolites of oenological relevance and we discuss its potential as a biocontrol agent in winemaking. Finally, biotechnological applications of W. anomalus beyond wine fermentation are briefly described. Keywords: non-Saccharomyces yeasts; Wickerhamomyces anomalus; Pichia anomala; enzymes; glycosidases; acetate esters; biocontrol; mixed starters; wine 1. -
Enzymatic Profiles and Antimicrobial Activity of the Yeast Metschnikowia Pulcherrima
Acta Innovations ISSN 2300-5599 2017 no. 23: 17-24 17 Ewelina Pawlikowska, Dorota Kręgiel Technical University of Lodz, Faculty of Biotechnology and Food Sciences, Institute of Fermentation Technology and Microbiology Wólczańska 171/173, 90-924 Lodz, [email protected] ENZYMATIC PROFILES AND ANTIMICROBIAL ACTIVITY OF THE YEAST METSCHNIKOWIA PULCHERRIMA Abstract The aim of the study was to characterize the antimicrobial properties of 5 strains belonging to the yeast species Metschnikowia pulcherrima. The antimicrobial activity of the strains was studied by observing pulcherrimin production and inhibition of microbial growth on YPG plates. Enzymatic assays were carried out using API ZYM tests. All strains of M. pulcherrima showed α-glucosidase and leucine arylamidase activities. The widest spectrum of activity was observed for strains NCYC2321, CCY145, and CCY149. All tested strains produced pucherrimin, and the yeasts Wickerhamomyces anomalus and Dekkera bruxellensis, the bacterium Bacillus subtilis and the moulds Penicillium chrysogenum and Aspergillus brasiliensis were the most sensitive to M. pulcherrima. Key words Metschnikowia pulcherrima, pulcherrimin, enzymatic activity, antagonism. Introduction As the world's population continues to grow, the global demand for food will also continue to increase. The ability to feed everyone depends upon the increase in food production and the length of storage capacity. The most popular way to prolong food usefulness is to use artificial chemicals such as pesticides. However, many of these substances are toxic to humans and are very harmful to the environment [1]. Due to the growing awareness of public opinion regarding the harmful effects to health and the environment, as well as the increasing resistance to pathogens, scientists have been interested in natural alternatives for a long time. -
Vaginal Yeast Infection a Vaginal Yeast Infection Is an Infection of the Vagina, Most Commonly Due to the Fungus Candida Albicans
5285 Anthony Wayne Drive, Detroit, MI 48202 (P) 313-577-5041 | (F) 313-577-9581 health.wayne.edu Vaginal Yeast Infection A vaginal yeast infection is an infection of the vagina, most commonly due to the fungus Candida albicans. Causes, incidence, and risk factors Most women have a vaginal yeast infection at some time. Candida albicans is a common type of fungus. It is often found in small amounts in the vagina, mouth, digestive tracts, and on the skin. Usually it does not cause disease or symptoms. Candida and the many other germs that normally live in the vagina keep each other in balance. However, sometimes the number of Candida albicans increases, leading to a yeast infection. A yeast infection can happen if you are: • Taking antibiotics used to treat other types of infections. Antibiotics change the normal balance between germs in the vagina by decreasing the number of protective bacteria. • Pregnant • Obese • Have diabetes A yeast infection is not a sexually transmitted illness. However, some men will develop symptoms such as itching and a rash on the penis after having sexual contact with an infected partner. Having many vaginal yeast infections may be a sign of other health problems. Other vaginal infections and discharges can be mistaken for vaginal yeast infection. Symptoms • Pain with intercourse • Painful urination • Redness and swelling of the vulva • Vaginal and labial itching, burning • Abnormal Vaginal Discharge • Ranges from a slightly watery, white discharge to a thick, white, chunky discharge (like cottage cheese) Signs and Tests A pelvic examination will be done. It may show swelling and redness of the skin of the vulva, in the vagina, and on the cervix. -
Targeting the Burkholderia Cepacia Complex
viruses Review Advances in Phage Therapy: Targeting the Burkholderia cepacia Complex Philip Lauman and Jonathan J. Dennis * Department of Biological Sciences, University of Alberta, Edmonton, AB T6G 2E9, Canada; [email protected] * Correspondence: [email protected]; Tel.: +1-780-492-2529 Abstract: The increasing prevalence and worldwide distribution of multidrug-resistant bacterial pathogens is an imminent danger to public health and threatens virtually all aspects of modern medicine. Particularly concerning, yet insufficiently addressed, are the members of the Burkholderia cepacia complex (Bcc), a group of at least twenty opportunistic, hospital-transmitted, and notoriously drug-resistant species, which infect and cause morbidity in patients who are immunocompromised and those afflicted with chronic illnesses, including cystic fibrosis (CF) and chronic granulomatous disease (CGD). One potential solution to the antimicrobial resistance crisis is phage therapy—the use of phages for the treatment of bacterial infections. Although phage therapy has a long and somewhat checkered history, an impressive volume of modern research has been amassed in the past decades to show that when applied through specific, scientifically supported treatment strategies, phage therapy is highly efficacious and is a promising avenue against drug-resistant and difficult-to-treat pathogens, such as the Bcc. In this review, we discuss the clinical significance of the Bcc, the advantages of phage therapy, and the theoretical and clinical advancements made in phage therapy in general over the past decades, and apply these concepts specifically to the nascent, but growing and rapidly developing, field of Bcc phage therapy. Keywords: Burkholderia cepacia complex (Bcc); bacteria; pathogenesis; antibiotic resistance; bacterio- phages; phages; phage therapy; phage therapy treatment strategies; Bcc phage therapy Citation: Lauman, P.; Dennis, J.J. -
Skin Immunity to Candida Albicans
TREIMM 1284 No. of Pages 11 Feature Review Skin Immunity to Candida albicans Sakeen W. Kashem1 and Daniel H. Kaplan2,* Candida albicans is a dimorphic commensal fungus that colonizes healthy Trends human skin, mucosa, and the reproductive tract. C. albicans is also a predomi- Primary immunodeficiencies reveal nantly opportunistic fungal pathogen, leading to disease manifestations such as conserved IL-17 stimulating/signaling disseminated candidiasis and chronic mucocutaneous candidiasis (CMC). The pathways involved in mucocutaneous differing host susceptibilities for the sites of C. albicans infection have revealed defense against C. albicans. tissue compartmentalization with tailoring of immune responses based on the Mouse models have demonstrated site of infection. Furthermore, extensive studies of host genetics in rare cases of both innate and adaptive sources of IL-17 in response to C. albicans. CMC have identified conserved genetic pathways involved in immune recogni- tion and the response to the extracellular pathogen. We focus here on human Immunity against C. albicans is com- and mouse skin as a site of C. albicans infection, and we review established and partmentalized towards sites of infection. newly discovered insights into the cellular pathways that promote cutaneous antifungal immunity. Non-hematopoietic cells provide anti- fungal immunity in the skin. Compartmentalization of Immunity Against C. albicans Skin Infection C. albicans is the most common and well-studied of the disease-causing Candida spp., and naturally colonizes the skin, genital, and/or intestinal mucosa in up to 70% of healthy individuals [1]. Under normal circumstances, the fungus does not cause disease but the absence of appropriate immune recognition and response mechanisms can lead to the inability to control C. -
Yeast Infection Division of Disease Control What Do I Need to Know?
Division of Disease Control What Do I Need To Know? Yeast Infection (Thrush, Diaper Rash, Vaginitis) What is a yeast infection? Yeast infections are caused by a fungus called Candida albicans. These infections can present in a variety of forms. Yeast infections in women can infect the vagina, called vaginitis. Thrush causes mouth infections in young infants and can also be a presenting sign of HIV infection in adults. Candida also may be the cause of many types of diaper rash in young children. Who is at risk for a yeast infection? Anyone can get a yeast infection. What are the symptoms of a yeast infection? Candidia diaper rash: The diaper area is red. The redness is worse in the creases. Redness is often bordered by red pimples. Rash may have a shiny appearance. Sores or cracking or oozing is present in severe cases. Thrush White patches appear on the inside of cheeks and gums and tongue. Thrush usually causes no other signs or symptoms. Vaginitis Vaginal irritation, intense itchiness and vaginal discharge. How soon do symptoms appear? Incubation period is unknown. How is a yeast infection spread? The fungus is present in the intestinal tract and mucous membranes of healthy people. A warm environment allows for growth and spread. Page 1 of 2 Last Updated: 01/2016 Person-to-person transmission may occur from a woman to her infant when the mother has a yeast infection in her vagina and in breastfeeding mothers whose babies with thrush infect the mothers’ nipples. When and for how long is a person able to spread the disease? A person can spread disease as long as the infection is present.